Ezetimibe Added to Statin Therapy: Efficacy, Safety, and Guideline Recommendations

LDL‑Cholesterol‑Lowering Efficacy

In patients receiving ezetimibe 10 mg daily as monotherapy, LDL‑C falls by approximately 18–20 % from baseline. 2
When added to a maximally tolerated statin, ezetimibe provides an additional ~25 % reduction in LDL‑C beyond the effect of the statin alone. 1
The American College of Cardiology notes that combination therapy yields significantly greater reductions in total cholesterol, LDL‑C, apolipoprotein B, and non‑HDL cholesterol compared with statin monotherapy, regardless of statin type. 1

Adding ezetimibe to statin therapy reduces major adverse cardiovascular events (MACE) by ~6 % (hazard ratio 0.94; 95 % CI 0.90–0.98). 1
In the IMPROVE‑IT trial, ezetimibe plus a moderate‑intensity statin in patients with a recent acute coronary syndrome lowered the composite endpoint (cardiovascular death, non‑fatal MI, unstable angina rehospitalization, revascularization, or non‑fatal stroke) over a median 6‑year follow‑up; absolute risk reduction was 2.0 percentage points (event rates 32.7 % vs 34.7 %). 1

Strong recommendation (Class I, Level A) to add ezetimibe to maximally tolerated statin when LDL‑C remains ≥ 70 mg/dL. 3
The European Society of Cardiology also recommends combination therapy if the LDL‑C goal of 55 mg/dL is not met with the maximum statin dose (Class I, Level A). 3

Weak recommendation (Class IIb) to consider ezetimibe when LDL‑C targets are unmet on statin alone, reflecting a modest benefit‑burden balance. 3
The Canadian Cardiovascular Society gives a Class IIa recommendation to add ezetimibe when LDL‑C is ≥ 70 mg/dL despite maximally tolerated statin therapy. 3

Strong recommendation against adding ezetimibe, as the incremental benefit does not outweigh the treatment burden. 3

The most common adverse effects are upper respiratory tract infection, diarrhea, arthralgia, sinusitis, and extremity pain. 2
The FDA label confirms ezetimibe is generally well tolerated, with generic formulations offering a cost‑effective option. 2

Risk assessment should use validated calculators (e.g., PREVENT equations) as endorsed in updated US guidelines. 3
Initiate maximally tolerated statin as first‑line therapy. 3
Add ezetimibe 10 mg daily when any of the following apply:

Contraindications: hypersensitivity to ezetimibe and moderate‑to‑severe hepatic impairment. 2
Drug interactions: administer ezetimibe ≥ 2 h before or ≥ 4 h after bile‑acid sequestrants; monitor when combined with cyclosporine or fibrates. 2
Pregnancy/Lactation: avoid use due to insufficient human safety data. 2
Shared decision‑making is recommended, especially for moderate‑risk patients, to balance modest absolute risk reductions against cost and treatment burden. 3